Vanda Pharmaceuticals (VNDA) Tops Q3 EPS by 16c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- US futures fall on tech selloff as concerns about hawkish Fed, AI spending mount
- SpaceX extends losses after $600 billion wipeout, tech stocks slide again
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Vanda Pharmaceuticals Reports Third Quarter 2018 Financial Results
November 7, 2018 4:01 PM ESTWASHINGTON, Nov. 7, 2018 /PRNewswire/ --Â Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the third quarter ended September 30, 2018.
Key Highlights:
Vanda reiterates 2018 net product sales guidance of $180 million to $200 million. Total net product sales from HETLIOZ® and Fanapt® were $49.1 million during the third quarter of 2018, a 4% increase compared to $47.4 million in the second quarter of 2018 and a 19% increase compared to $41.3 million in the third quarter of 2017.HETLIOZ® (tasimelteon)
HETLIOZ® net product sales were $29.9 million in... More